Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BDC-4182 |
| Synonyms | |
| Therapy Description |
BDC-4182 is an immune-stimulating antibody conjugate (ISAC) consisting of an antibody targeting CLDN18.2 linked to a TLR7/8 agonist, which potentially induces anti-tumor immune activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BDC-4182 | BDC4182|BDC4182 | CLDN18.2 Antibody 23 | BDC-4182 is an immune-stimulating antibody conjugate (ISAC) consisting of an antibody targeting CLDN18.2 linked to a TLR7/8 agonist, which potentially induces anti-tumor immune activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06921837 | Phase Ib/II | BDC-4182 | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | Recruiting | AUS | 2 |